| News
Roche diabetes app replaces blood glucose meter
10.12.2019
Diabetes patients can use an app developed by Roche to determine their blood sugar levels on the basis of two photos taken on a cell phone camera. The Basel-based pharma group has now received the CE Mark for its app, paving the way for it to be marketed throughout Europe and in other countries around the world.

Roche in Basel (img: Roche)
Roche has removed the need for diabetes patients to use blood sugar measuring devices. The Accu-Chek Sugar View app developed by the Basel-based pharmaceutical company allows blood sugar levels to be tested using special test strips and two photos taken with a cell phone camera, as outlined in a press release. Roche has now received the CE Mark for its app, which confirms that the product complies with the applicable requirements. The CE Mark is a prerequisite for successful marketing across Europe and in other countries.
Roche will now make the app widely available for certain smartphone models via the Google Play Store. “The broad launch of this state-of-the art digital solution can offer a huge benefit to people in-between doctors’ visits and to those not having access to appropriate diabetes care and blood glucose monitoring”, explained Marcel Gmünder, Global Head of Roche Diabetes Care, in the press release. An additional advantage is that the app represents an affordable solution for those suffering from diabetes, Gmünder commented further.
Users take an Accu-Chek Active test strip and then take two photos on their smartphone camera. The app leads the user through an easy-to-follow process until a dedicated algorithm assigns the blood glucose result on the test strip to one of the categories ranging from “low” to “very high”. Based on this assessment, the user receives suggested actions including, for example, a prompt to eat something.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Cell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read MoreBLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read MoreCombatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read MoreAMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read MoreInvestors give Resistell 8.5 million Swiss francs
Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...
Read MoreBSI integrating AI from Parashift in banking software
Parashift, the specialist in the area of smart document processing on the basis of Artificial Intelligence (AI), has entered into...
Read MoreUptownBasel joins IBM Quantum Network
UptownBasel is partnering with IBM. The emerging competence center for Industry 4.0 will provide its partners with the IBM Quantum...
Read MoreSouth Korean pharma firms show interest in the Basel Area
Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...
Read MoreGamma Technologies acquires ProFEMAG portfolio
The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...
Read MoreDatabaum establishes headquarters in Basel
Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...
Read More